dromlakhani Provide fertility preservation counseling before gender-affirming treatment
STEP 1 — Gather Information
Collect patient’s assigned sex at birth, gender identity, pubertal status (Tanner stage), mental health assessment confirming capacity to consent, eligibility for pubertal suppression (Tanner G2/B2 or later) or hormonal therapy, desire for biological children, and any medical contraindications to fertility preservation procedures.
STEP 2 — Rule In / Rule Out
Rule in: patient is seeking gender-affirming medical treatment (puberty suppression or sex hormone therapy) and is about to start; rule out: patient not eligible for or not imminently beginning such treatment → defer fertility preservation counseling until eligibility is confirmed.
STEP 3 — Classify or Stratify
Classify by reproductive potential: for patients assigned male at birth, assess feasibility of sperm cryopreservation (post‑pubertal) vs. future spermatogenesis after GnRH analog cessation; for patients assigned female at birth, assess oocyte/embryo cryopreservation (post‑menarche) or experimental ovarian tissue cryopreservation; note that prepubertal patients have limited current options.
STEP 4 — Decide
Provide tailored fertility preservation counseling, discuss success rates, risks, and timing relative to gender‑affirming treatment, refer to reproductive specialist if desired, document the discussion and patient’s decision, then proceed with pubertal suppression or hormonal therapy per the patient’s informed consent.
Clinical Guardrails / Mimics / Pitfalls
Do not assume lack of fertility interest based on gender identity; avoid delaying necessary gender‑affirming care solely for fertility preservation; do not overstate success rates of experimental techniques; remember that GnRH analog suppression is reversible but fertility recovery data are limited; always involve a mental health provider in assent/consent processes for adolescents; do not omit discussion of fertility options when counseling about hormone risks.
Concrete Clinical Example
A 14‑year‑old transgender male (assigned female at birth) at Tanner G2 presents for GnRH analog initiation. Clinician confirms eligibility, discusses that sperm cryopreservation is not feasible pre‑pubertally, explains that spermatogenesis may resume after stopping GnRH analogs (data scarce), refers to reproductive endocrinology for future options, and after shared decision‑making the patient proceeds with pubertal suppression.
Source: Endocrine Treatment of Gender-Dysphoric/Gender-Incongruent Persons: An Endocrine Society Clinical Practice Guideline, Endocrine Society, 2017, DOI:10.1210/jc.2017-01658